Caplyta Doubles Depression Relief for Anxious Patients in New Subgroup Analysis
· techtimes.com · popularity 20/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Caplyta MDD subgroup analysis in the Journal of Clinical Psychiatry finds lumateperone's effect size nearly doubles in major depressive disorder patients with the DSM-5 anxious distress specifier, rising from 0.44 to 0.85 on the MADRS. The 481-patient Study 501 post-hoc analysis finds a response NNT of three in this subgroup, representing about 43% of all MDD patients.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 3.